TickerFacts.

Elutia Inc. (ELUT): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2020-12-31, 2022-12-31, 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$4.16M
Year ended 2025-12-31
$9.27M2019-12-31: $2.40M2020-12-31: $5.95M2021-12-31: $9.27M2022-12-31: $7.73M2023-12-31: $4.40M2024-12-31: $3.00M2025-12-31: $4.16M$4.16M
2019-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$4.16M+38.9%2026-03-13, From 2025-01-01
2024-12-31$3.00Mn/c2026-03-13, From 2024-01-01
2023-12-31$4.40M-43.1%2025-03-11, From 2023-01-01
2022-12-31$7.73Mn/c2024-03-11, From 2022-01-01
2021-12-31$9.27M+55.6%2023-03-23, From 2021-01-01
2020-12-31$5.95Mn/c2022-03-08, From 2020-01-01
2019-12-31$2.40Mn/a2021-03-15, From 2019-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Elutia Inc. (ELUT)2025-12-31$4.16M+38.9%
Passage BIO, Inc. (PASG)2025-12-31$23.28M-42.1%
Cardiff Oncology, Inc. (CRDF)2025-12-31$35.33M-4.1%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$112.67M+1.0%
Fennec Pharmaceuticals Inc. (FENC)2025-12-31$250.0K-18.6%
Senti Biosciences Holdings, Inc. (SNTI)2025-12-31$37.59M+9.4%
Armata Pharmaceuticals, Inc. (ARMP)2025-12-31$23.72M-31.1%
Alpha Cognition Inc. (ACOG)2025-12-31$1.87M-52.4%
Cognition Therapeutics Inc (CGTX)2025-12-31$37.19M-10.8%

Compare ELUT, PASG, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗